key: cord-0814090-7xbm2mtc
authors: Vasiliadou, Ifigenia; Noble, David; Hartley, Andrew; Moleron, Rafael; Sanghera, Paul; Guerrero Urbano, Teresa; Schipani, Stefano; Gujral, Dorothy; Foran, Bernie; Bhide, Shree; Haridass, Anoop; Nathan, Kannon; Michaelidou, Andriana; Sen, Mehmet; Geropantas, Konstantinos; Joseph, Mano; O'Toole, Lorcan; Griffin, Matthew; Pettit, Laura; Chambers, Jonathan; Jankowska, Petra; De Winton, Emma; Goranova, Rebecca; Singh, Niveditha; Shah, Ketan; Kong, Anthony
title: A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic
date: 2021-06-30
journal: Clin Transl Radiat Oncol
DOI: 10.1016/j.ctro.2021.06.002
sha: 538fa913e627447ac873946c760f371253050d09
doc_id: 814090
cord_uid: 7xbm2mtc

BACKGROUND: The onset of the COVID-19 pandemic necessitated rapid changes to the practice of head and neck oncology. This survey was conducted to assess the pre-Covid-19 pandemic standard of practice for head and neck oncology patients and the treatment modifications introduced during the Covid-19 pandemic in UK. METHODOLOGY: The UK National Cancer Research Institute (NCRI) Head and Neck Clinical Studies Group initiated a multi-centre survey using questionnaire to investigate the effect on feeding tube practice, radiotherapy (RT) fractionation and volumes, use of chemotherapy in the neo-adjuvant, adjuvant and palliative setting, the use of immunotherapy in the palliative setting, access to radiology and histopathology services, availability of surgical procedures. RESULTS: 30 centres were approached across UK; 23 (76.7%) centres responded and were included in the survey. There were differences in the standard practices in feeding tube policy, RT dose and fractionation as well as concurrent chemotherapy use. 21 (91%) participating centres had at least one treatment modification. 15 (65%) centres initiated a change in radical RT; changing to either a hypofractionation or acceleration schedule. For post-operative RT 10 centres (43.5%) changed to a hypofractionation schedule.12 (52.2%) centres stopped neo-adjuvant chemotherapy for all patients; 13 (56.5%) centres followed selective omission of chemotherapy in concurrent chemo-radiotherapy patients, 17 (73.9%) centres changed first-line chemotherapy treatment to pembrolizumab (following NHS England’s interim guidance) and 8 (34.8%) centres stopped the treatment early or offered delays for patients that have been already on systemic treatment. The majority of centres did not have significant changes associated with surgery, radiology, histopathology and dental screening. CONCLUSION: There are variations in the standard of practice and treatment modifications for head and neck cancer patients during Covid-19 pandemic. A timely initiative is required to form a consensus on head and neck cancer management in the UK and other countries.

 We investigated the effect of COVID-19 pandemic in the treatment practice of head and neck oncology patients in the UK  There is variability in practice in feeding tube policy, radiotherapy fractionation and schedule as well as concurrent chemotherapy and palliative systemic treatment use across the UK oncology centres  15/23 participating centres (65%) changed to either a hypofractionation or acceleration schedule during COVID-19 pandemic  12/23 participating centres (56.5%) followed selective omission of concurrent chemoradiotherapy  There are variations across UK centres for the standard practice as well as treatment modifications during Covid-19 pandemic; a timely consensus on head and neck cancer management and guidance on treatment modifications for future pandemic is required

Coronavirus disease 2019 (COVID-19) is highly contagious and caused by the SARS-CoV-2 virus that is mainly spread by respiratory secretions (1) . It was first recognised following an outbreak of the disease in December 2019 in Wuhan, China. It was declared as a global pandemic by the World Health Organisation on 11 th March 2020 (2) . Retrospective evidence produced early in the pandemic from China indicated that cancer patients, including those receiving treatment for cancer were at increased risk of serious COVID-19 morbidity, including the need for ventilator support or death (3) . However, later studies including a larger number of patients have shown that the mortality for cancer patients with COVID-19 appears to be principally driven by the patients' other co-morbidities, age and gender rather the use of anticancer treatment (4) . Nevertheless, there may be a difference in patients with haematological cancers since some of these patients with SARS-CoV-2 infection have worse outcomes compared with both the general population with SARS-CoV-2 and patients with haematological malignancies without COVID-19 while the immune signatures of SARS-CoV-2 positive solid cancer patients resembled those for SARS-CoV-2 positive non-cancer patients (5) . This may be related to some of the patients with B cell-related haematological cancers have continued viral shedding without developing antibodies for a prolonged period (6) .

Since the outbreak of COVID-19, oncology departments have had to consider risk mitigation strategies for patients both because of reduced availability of radiographers and chemotherapy nurses due to sickness, self-isolation or staff redeployment and concerns regarding the possible consequences of anticancer treatment or of potential exposure of patients to risks of viral transmission during their visits to the hospital (7) . The outcomes for patients with head and neck squamous cells carcinoma (HNSCC), depend on a number of factors, not least HPV status (8) . Recent data suggest 84.6% 5-yr overall survival (9) and 97.5% 2-yr overall survival (10) for better prognosis HPV-driven disease whilst mortality is much higher for high-risk HPV-negative tumours with a 3-year overall survival of 57.1% (8) . HNSCC poses particular problems due to frequent visits required for a course of radical chemoradiotherapy. Moreover, there is a significant risk of aerosol generation during diagnostic workup for patients with HNSCC, and there is evidence from China, Italy, and Iran, of increased transmission rates to otolaryngologists (11) . A number of guidelines have been published from both surgical and oncology networks at institutional, national and international levels to assist clinicians in the safe delivery of services based on the new challenges faced (12) (13) (14) (15) (16) .

The American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) published practice recommendations for radiation oncologists involved in the care of head and neck cancer patients in April 2020 (12) . The aim of the current study, initiated by NCRI Head and Neck Clinical studies group, was to survey UK head and neck oncologists regarding both standard practice pre-pandemic and the treatment modifications introduced for head and neck cancer patients during the first wave of the COVID-19 pandemic.

The UK National Cancer Research Institute (NCRI) Head and Neck Clinical Studies Group initiated a multi-centre survey by distributing an excel (with word version) questionnaire containing 21 questions to head and neck clinical oncologists at different UK centres to assess pre-pandemic standard treatments and the treatment/practice modifications introduced. The questionnaire was designed to investigate the effect of the first wave of the pandemic on prophylactic or reactive use of feeding tubes, access to radiology and histopathology services, availability of diagnostic and therapeutic surgical procedures, radiotherapy fractionation and volumes, use of chemotherapy in the neo-adjuvant, concurrent and palliative setting and the use of immunotherapy in the palliative setting.

The questionnaire was sent out in July to September 2020 to a total of 30 centres across UK and all replies were collected by December 2020. This survey covered the period between February 2020 to July 2020 which is the period following the first wave of COVID-19 pandemic. The questionnaire included a total of 9 main domains with further questions in each domain as evident in the appendix. The survey aimed to investigate changes in patterns of practice across head and neck oncology units in general, and did not specify response stratification by primary site or histological subtype. Therefore, whilst the majority of data presented pertain to patients with HNSCC, changes in practice for salivary gland tumours, and cutaneous cancers of the head and neck are also represented.

Thirty centres were approached and twenty three (76.7%) oncologists from different cancer centres responded and participated in the survey including those from Guys Cancer Centre, Leeds Cancer Centre, Beatson Glasgow Centre, Imperial College Healthcare NHS Trust (London), Weston Park 21 (91%) centres had at least one treatment modification and this commenced in March 2020 during the peak of the first wave. 9/23 (39.1%) applied changes to standard practice for 2 months, 8/23 (34.8%) for 3 months, 3/23 (13.0%) for 4 months and 1/23 (4.3%) for 7 months (change in radiotherapy fractionation maintained until October 2020). All centres initiated modifications based on the increase in incidence and the risk of complications and mortality from exposure to SARS-CoV-2 infection. Most clinicians attempted to reduce the number of visits and thus reduce the risk of the patients getting infected with the virus. Although two centres did not report any treatment modification during this period, one of the centres adopted a watch and wait approach on new systemic treatment and the other centre used pembrolizumab as 1 st line systemic treatment for recurrent or metastatic HNSCC in the palliative setting following NHS England's Interim Guidance on pembrolizumab (17) . The two centres with no modifications reported low incidence of Covid-19 infection in the geographical area covered by the unit surveyed and thus did not see any need for treatment modifications

We found that the feeding tube practice for head and neck cancer patients undergoing radical radiotherapy treatment varies across UK. Most centres (18/23; 78.3%) reported the use of elective/prophylactic percutaneous endoscopic gastrostomy (PEG) or radiologically inserted gastrostomy (RIG) for most patients or specifically for patients undergoing bilateral neck irradiation and/or concurrent chemotherapy. A smaller number of cancer centres (5/23; 21.7%) reported a reactive policy of nasogastric/nasojejunal tube (NGT/NJT) inserted during radiotherapy when patients experience difficulty in swallowing with elective RIG/PEG being reserved for those with pre-existing or deemed to have imminent swallowing or aspiration problems during radiotherapy. Eight (34.8%) centres changed their feeding tube practice during Covid-19 pandemic: two centres (8.7%) changed their practice from reactive to elective feeding tube, five centres (21.7%) changed from elective/prophylactic PEG/RIG to reactive NGT (three centres reported that this was due to reduced capacity for the procedure) and one centre (4.3%) changed from prophylactic gastropexy to PEGs due to restrictions in local endoscopy service (table 1 and figure 1)

The survey demonstrated variation in the standard primary radical radiotherapy fractionation used for head and neck cancer patients across the cancer centres. The 70Gy/35 fractions/46 days (70Gy/35#) fractionation is regarded as gold standard worldwide and is more commonly used at many cancer centres throughout the world. In this survey, it is still used at 6/23 (26.1%) participating centres while the majority of the centres (17/23) (73.9%) have adopted 65Gy/30 fractions/39 days (65Gy/30#). One centre uses 70Gy/35 fractions undergoing concurrent chemoradiation but uses 65Gy/30 fractions for patients undergoing radical radiotherapy alone.

During the Covid-19 first wave peak, fifteen (65%) centres initiated a change in radical radiotherapy fractionation schedule (table 2 and figure 2 ). For those centres that where 70Gy/35# was standard, this fractionation continued to be used for some younger and fit patients while selected patients (including those older and those with co-morbidities) received 65Gy/30#, DAHANCA (18) (68Gy/34# x 6/week) instead of concurrent chemoradiation or 55/20# (small volume). For those centres that use 65Gy/30# as their standard fractionation, treatment modification included 55Gy in 20# (either all or selected patients such as those with co-morbidities or older patients) or 50Gy/15# (small volumes) and 3 centres used 68Gy/34#/6 fractions per week (DAHANCA) instead of chemoradiation (18) . For early larynx SCC T1/T2N0M0, 55Gy/20# is the standard fractionation but during Covid-19 pandemic, one centre used 50Gy/16# as an option for T1 larynx SCC and another centre used 50Gy/15# or 50Gy/16#.

For postoperative radiotherapy (PORT), the standard practice for UK centres was generally consistent, using 60Gy/30# (64-66Gy/32-33# for high risks such as positive margin or extracapsular spread at some centres). Ten (43.5%) centres reported changing their standard PORT fractionation to 50Gy or 55Gy in 20# (either for all patients or for selected patients such as those with co-morbidities or older patients and those undergoing small volume and unilateral radiotherapy treatment at some centres) (table 2). In addition to using 50-55Gy/20# for PORT, one centre stated that they discussed pros and cons of not having PORT in intermediate risk patients with comorbidities and omission of chemotherapy and use of PORT +/-boost in high-risk patients. One centre used 60Gy/30# with simultaneous integrated boost (SIB), 65Gy/30# to high-risk volume (in place of concurrent chemoradiation) while using 50Gy/20# for small volumes.

For palliative radiotherapy fractionation, four (17.4%) centres have reported a change with three centres avoided using radiotherapy longer than 1 week (e.g. 25Gy/5#, 20Gy/5# or 8Gy/1#) and one centre changed from 45Gy/15# to 27Gy/6#/twice weekly. One centre reported no change for most patients but considered 27Gy/6#/twice weekly if needed. Most other centres did not change palliative fractionation and used 20Gy in 5 fractions and/or 8Gy in 1 fraction while 3 centres continued to use 14Gy/4# (twice a day and at least 6h apart, for 2 consecutive days, repeated at 4 weekly intervals for a further two courses if no disease progression) (19) .

Only three centres (13%) reported changing their radiotherapy delineation protocols. One centre adopted the international consensus target delineation guidelines (5+5 margin) (20) for primary and nodal GTV in selected patients; those with easily identified tumours in CT planning scan and those with MRI planning scan) and selected cases had modified target volume delineation including omitting contralateral nodal irradiation with possible reduction in ipsilateral nodal irradiation to include only the level adjacent to involved nodes except retropharyngeal node and avoided irradiation to the lung apices. A further centre changed the volume delineation for elderly high risk PORT patients by offering unilateral rather than bilateral neck radiotherapy, in selected cases, in an attempt to reduce the overall burden of acute toxicity, and the need for hospital admission. At one centre, standard delineation was carried out in most patients although small adaptation was applied to reduce the extent of prophylactic level 4 neck nodal volumes inferiorly to minimise irradiation to lung apices and prophylactic irradiation to the higher retropharyngeal (RP) lymph nodes was excluded where the risk of spread was low. In addition, unilateral treatment was considered in moderate risk or frail patients.

3.3.1 Neo-adjuvant chemotherapy: Neoadjuvant chemotherapy is usually only given to selected patients at most cancer centres including those with nasopharyngeal cancer or those with heavier disease burden or positive nodal disease. During the COVID-19 pandemic, twelve (52.2%) centres stopped giving neoadjuvant chemotherapy treatment to all patients and 8 (34.8%) centres were giving neo-adjuvant chemotherapy to very exceptional cases including young patients, those with significant disease related symptoms or those with nasopharyngeal cancers. If given, it was reported that neoadjuvant treatment was given either with dose reduction (75% Cisplatin), 2 drugs (instead of 3 drugs combination like docetaxel, cisplatin and 5FU chemotherapy) and/or with GCSF cover. One (4.3%) centre was giving neo-adjuvant chemotherapy with dose reduction (75% Cisplatin). Two (8.7%) centres reported no change in the neo-adjuvant chemotherapy standard practise (figure 3a).

3.3.2 Concurrent chemotherapy: One (4.3%) centre omitted chemotherapy for all patients. Thirteen (56.5%) centres omitted chemotherapy in selected cases (e.g. >60 or if DAHANCA radiotherapy fractionation is used or after discussion with selected patients). At one of these centres patients were given the option to omit following detailed discussion of risk versus benefit. All but 2 patients at this centre chose to carry on with concurrent chemotherapy. Three (13%) centres changed cisplatin to carboplatin for all patients, whereas one centre changed to carboplatin for only selected patients. Two (8.7%) centres changed the cisplatin schedule from 3 cycles to 2 cycles (standard radiotherapy fractionation at these centres was 70Gy/35#; one centre gave GCSF cover and one centre gave reduced dose). One (4.3%) centres changed treatment to week 1 and week 5 instead of three weekly, one (4.3%) centre changed from three weekly cisplatin to weekly and one (4.3%) centre omitted cycle 2 of treatment for majority of patients already on concurrent chemoradiation. One (4.3%) centre changed cisplatin to 75% of dose with the same schedule and three (13.0%) centres did not change treatment (figure 3a).

Seventeen (73.9%) centres changed 1 st line palliative systemic chemotherapy treatment to pembrolizumab for recurrent or metastatic HNSCC following NHS England's interim guidance and approval of pembrolizumab for eligible patients. Five centres (21.7%) followed either a 'watch and wait' approach or delayed all referrals. One (4.3%) centre did not change palliative 1 st line treatment practice (figure 3a).

Ten (43.5%) centres did not change chemotherapy treatment for patients on treatment, eight (34.8%) centres stopped the treatment early or offer delays during lockdown, one (4.3%) centre reduced dose to 75% and stopped cetuximab, one (4.3%) centre changed cetuximab from weekly to two weekly. One (4.3%) centre stopped only 3 rd line chemotherapy with two (8.7%) centres decision was taken on individual basis (figure 3a).

3.6 Second-line immunotherapy (nivolumab) post platinum chemotherapy progression:

Twelve (52%) centres changed nivolumab treatment from 2-weekly to 4-weekly. Nine (39%) centres did not make any change to nivolumab treatment (one centre changed some to 4 weekly based on individual discussion). Two (8.7%) centres offered a treatment break during lockdown (figure 3a).

Fourteen (64.8%) centres had no change in surgical practice. Seven (30.4%) centres had changes in selected cases where it was decided to deliver primary radiotherapy instead of surgery due to various reasons including limited access to theatre or intensive care unit (figure 3b). One centre (4.3%) did not proceed to surgery in high-risk cases with low chance of cure which might have been attempted before Covid-19 pandemic and these patients were not treated radically. At one centre (4.3%), the maxillofacial team undertook local resection and omitted neck dissections in cN0 high risk patients and replaced with close surgical FU instead. Since the trial recruitment for PATHOS (Post-operative Adjuvant Treatment for HPV-positive Tumours) was suspended nationally during this time, patients who would have been offered the trial were treated with definitive radiotherapy instead for the duration for the trial as per the standard of care at their cancer centres.

The radiologist assistance during target volume contouring remained the same in eighteen (78%) centres and it was not applicable in 5 centres. Moreover, twelve (52.2%) centres had the same capacity for scans. Ten (43.5%) centres performed only urgent scans and one (4.3%) 1 centre had delays in imaging. Sixteen (70%) centres had no delays in reporting; eight (30%) centres had only minor delays in reporting (figure 3b).

Twenty-two (95.7%) centres had no change in histopathology reporting while only one (4.3%) centre has some delays in reporting (figure 3b).

Dental screening: Eighteen (82%) centres had no change in dental treatment; four (17.4%) centres had some changes in dental practice with one (4.3%) having telephone-based prevention advice and two (8.7%) that stopped their service. Ten (43.5%) centres had no change in dental monitoring; ten (43.5%) centres their treatment was cancelled or deferred; two (8.7%) centres changed to telephone consultation (figure 3b).

COVID-19 screening pre-treatment and other changes Twelve (52.2%) centres performed pre-treatment COVID swab test since the pandemic and four of these centres reported doing swabs weekly during treatment. Most centres have introduced several safety measures including personal protective equipment (PPE) use, reducing face to face consultation and increasing the use of video or telephone consultation, limitation of visitors to cancer centres, temperature check for patients and visitors, symptomatic and/or Covid-19 positive patients to have either treatment delay and/or to have treatment at a separate machine or the end of the day if it was deemed absolutely necessary to have treatment.

The onset of the COVID-19 epidemic necessitated swift changes to the practice of head and neck oncology. This was facilitated by guidelines produced by a range of specialist professional organisations, as well as by guidance from central authorities such as NHS England, and included changes to rigid commissioning and funding rules including those for the Cancer Drugs Fund (12) (13) (14) (15) (16) . However, there was an inevitable delay between the onset of the pandemic and these publications, let alone any pertinent clinical data to guide decision making in the era of COVID-19. Therefore, as case numbers increased exponentially throughout the country in March and April, individual cancer centres had to make decisions about how standard treatment protocols should, or should not, be amended in the absence of any guidelines or consensus. We were particularly interested in the changes introduced following the first wave when oncologists were uncertain what to do, having never encountered this previously. We covered the survey between February to July 2020 since most centres had resumed normal practice by the end of June 2020 when the Covid-19 restrictions started to ease in the UK (although the survey found out that one centre had changes lasted until October 2020).

That individual centre responses should vary was inevitable. Not only were there significant differences in rates of COVID-19 infection, hospitalisation and pressures on ITU beds across the country during this time, but centres faced heterogeneous practical challenges such as the physical layout of departments, size of waiting rooms, availability of slots for systemic therapy, and staffing issues, in addition to the pressures on allied services such as surgery and radiology as seen in our data. Therefore, it is reasonable to suppose that each surveyed centre was faced with its own unique set of specific challenges, within the context of the broader national response to the pandemic.

Despite this, there are some clear trends in the ways in which clinicians responded to the challenges of COVID-19. With regards to radiotherapy fractionation schedules, 2 interesting themes emerge. Firstly, that 65Gy in 30 fractions over 6 weeks has been widely accepted across the country as standard practice, with 17/23 surveyed centres (73.9%) reporting that this schedule was a standard protocol option before the onset of the pandemic. In contrast, 2Gy per fraction schedules (70/35) were used by only 6/23 (26.1%) of centres. Secondly, we observed a clear trend towards centres increasing dose per fraction, and/or reducing overall treatments during the pandemic. Fifteen of 23 surveyed centres (65.2%) changed practice to incorporate a schedule that did at least one of these things, for at least some patients treated at that centre, early in the pandemic. The use of radical hypofractionated radiotherapy courses in this context did have some randomised controlled trial (RCT) data to support it (18) . However, responses from centres infer that decision-making was also pragmatic, weighing up possible reductions in efficacy by implementing such regimes, with the risks of not reducing acute toxicity, footfall, and overall treatment as the pandemic approached its zenith. It is worth stating that amongst individual centres having their own heterogenous challenges, national guidance from the Royal College of Radiologists (Clinical Oncology) was strongly advocating consideration of hypofractionation to reduce footfall and risk of infection (21) .

This theme of there being broad alignment in the use of first principles to guide decision making, with more superficial heterogeneity in the application of these principles to daily practice, is also seen in our data on systemic therapy. In general, survival benefits with the addition of concomitant systemic therapy to radical radiotherapy in patients with HNC are modest (22). Weighing against this, the addition of cisplatin chemotherapy to radical radiotherapy regimes, requires long infusion times in hospital, an increased risk of toxicity requiring emergency management, and some direct risks of immunosuppression, which was naturally a concern during the pandemic. Furthermore, the delivery of chemotherapy in some areas was compromised by staff availability, and even where this was less problematic the modest survival benefit had to be balanced against the short-term perceived risks related to the effects of COVID-19. The latter were clearly difficult to quantify, although groups at risk of severe COVID were identified early in the pandemic (23) .

This balance of risks is reflected in the data pertaining to concomitant therapy, with 12/23 centres (52.2%) either omitting concomitant therapy altogether, or in selected cases. In addition, for centres where concomitant therapy was continued during the pandemic (11/23 -47.8%), many chose to reduce total dose, or dose density, or switch to a regime thought to be less immunosuppressive, or add GCSF, in an attempt to mitigate perceived risks. Interestingly, 2 centres either started or increased their use of the accelerated DAHANCA regimen, whilst reducing use of concomitant systemic therapy, on the basis that this protocol confers similar additional disease control benefits, and acute toxicity risks relative to the addition of systemic therapy to standard fractionation approaches, but without the immunosuppression (18) .

The data in this study confirm our pre-conception that feeding tube practice is highly variable across UK centres. Again, this is not surprising, as evidence for one feeding tube policy being more efficacious is inconclusive; a review investigating different nutritional policies concluded that there was insufficient evidence to determine the optimal method of enteral feeding (24) . However, the data also show similar trends in the way issues around feeding tubes were managed during the pandemic. The fact that 15/23 (65.2%) of centres reported no change to practice suggests that clinicians were generally reluctant to amend this aspect of treatment protocols unless determined by necessity. Interestingly, 2 centres (8.7%) switched from reactive to elective feeding tube insertion in an attempt to reduce the risk of acute hospital admission during the pandemic, whilst five of 23 centres (21.7%) had to switch from elective feeding tubes to reactive NGT, due to reduced capacity and access to endoscopy. However, in our view, it is a testament to our colleagues across the multi-disciplinary team that this proportion was so low, given the extreme pressures on hospitals at the time.

As seen with practice changes in both radiotherapy and systemic therapy, the range and magnitude of additional pressures seen in the early stages of the pandemic had an inevitable effect on surgical practice -notably the big reduction in access to ITU beds. However, recent evidence has highlighted the safety of head and neck surgical practice during the COVID-19 pandemic (25) . Interestingly, where surgery was omitted, radiotherapy and/or chemotherapy was considered as a substitute or a temporising measure, slightly in conflict with the logic of arguments detailed above. Furthermore, where surgery could and did take place, this triggered further debate in the use, and technical details, of postoperative radiotherapy. Some evidence supported the indications and doses for treatment and helped to quantify the benefits of chemotherapy in this setting (26, 27) .

Our results are consistent with ASTRO/ESTRO recommendations, which were published during the peak of the 1 st wave of the pandemic in April 2020 (12) . First of all, there was a strong agreement to suggest hypofractionation radiation schedule in case of severely reduced radiation therapy capacity; however, these changes were implemented during the risk mitigation phase in a lot of centres (61% of centres offering hypofractionation schedule to all or selected patients). Moreover, there was a strong agreement to continue with the use of concurrent chemotherapy with numerous panellists stating they would consider changing to weekly cisplatin. However, it was recognised that the use should be restricted in patients with a higher risk of more serious SARS-COV-2 infection such as patients with comorbidities or of older age. This is also evident on the results of the survey with only one centre (4.3%) omitting chemotherapy for all patients and thirteen (56.5%) omitting in selected cases deemed as highrisk of infection and mortality. This was in agreement with the national guidance from the Royal College of Radiologists (Clinical Oncology) (21) , which advocated omission of concurrent chemotherapy in patients over 60 years old or in those with significant comorbidity. Finally, there was a strong agreement not to increase the use of prophylactic feeding tube. As highlighted above, there are underlying discrepancies on feeding tube practice across UK centres. During the first wave of COVID-19 pandemic, 14/23 (60.9%) centres were using prophylactic feeding tubes with 2 of those centres changing their policy from reactive to prophylactic during the first wave.

One focus of the UK NCRI Head and Neck Clinical Studies Group has been to consider whether the changes instituted due to the epidemic present an opportunity to answer clinical research questions. The interventions described were generally short term, and implemented quickly, and often simultaneously across the country (and indeed internationally). It is relatively easy to identify the patients affected because the time at which clinical decisions and treatments were made is clearly defined. However, as we have demonstrated, centres across the country took differing approaches, changing management in a heterogeneous manner depending on local oncological and epidemiological considerations, and for varying lengths of time. Data on short term outcomes such as toxicity is poorly collected and not standardised outside clinical trials. Collection of long-term outcomes such as recurrence, feeding tube dependency, other quality of life outcomes and even death is also poor, and national initiatives to improve data quality following the Data Audit for Head and Neck Oncology (DAHNO) have faltered. Thus, whilst the notion of learning as much as we can from the pandemic is both scientifically and ethically laudable, we suggest that the problems described will confer very significant methodological challenges for those seeking to do so.

So what can be learned from the experience in Head and Neck oncology during the pandemic of 2020? This study shows that whilst the details of crisis response across the nation were heterogeneous, there were clear trends in the principles and logic that clinicians applied to weigh the relevant risks, before clinical data or consensus expert opinion was available to help frame these decisions. Furthermore, the study also shows considerable variation in many aspects of practice prior to the onset of the pandemic. Whilst the fundamentals of treatment for HNSCC are similar across the country, there is a lack of baseline consensus on the detailed application of issues as diverse as prophylactic dental management, feeding tube placement, radiotherapy fractionation and chemotherapy drugs and doses. We aim to collect the treatment and survival outcome data on some of these affected patients who had treatment modifications, which may provide lessons to be learnt for future pandemics. Moreover, it will be interesting to assess outcomes and the effect of delays to diagnosis and treatment as the delays reported in this survey were subjective and we did not report actual metrics.

In summary therefore, these data present an interesting paradox. In one sense, it is reassuring that centres across the country applied such similar approaches to dealing with the 'once in a generation' crisis presented by COVID-19. However, the crisis has also exposed underlying discrepancies in standard practice, and may provide an impetus to change. A timely initiative from the Royal College of Radiologists seeks to form a consensus on UK head and neck cancer management, as has been achieved in other tumour sites (28) 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

COVID-19) outbreak -WHO announces COVID-19 outbreak a pandemic

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. The Lancet

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. The Lancet Haematology

Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients

Head and neck cancer care in the COVID-19 pandemic: A brief update

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. The Lancet

Position Statement: Otolaryngologists and the COVID-19 Pandemic | American Academy of Otolaryngology-Head and Neck Surgery

Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement

Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus

NHS England interim treatment options during the COVID-19 pandemic

Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era

Based Guidelines for Management of Head and Neck Mucosal Malignancies during the COVID-19 Pandemic

Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial

QUAD SHOT" -A phase II study of palliative radiotherapy for incurable head and neck cancer

Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma

Head and neck cancer and COVID-19

Royal College of Radiologists website

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology

COVID-19: review of disparities in risks and outcomes -GOV.UK [Internet

Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy

Head and neck cancer surgery during the COVID-19 pandemic: An international, multicenter, observational cohort study

Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: A systematic review with meta-analysis

Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer

Development of Postoperative Radiotherapy for Breast Cancer: UK Consensus Statements -a Model of Patient

Guys Cancer Centre Primary:65Gy/30# PORT: 60Gy/30# Primary: 55Gy/20#/50Gy/15-16# (small volume)

Leeds Cancer Centre Primary: 70Gy/35#/7wks (For RT only 65Gy/30#/6 weeks) PORT: 60-66Gy/30-33# Primary: 65Gy/30# PORT

Beatson Glasgow Centre Primary:65Gy/30# high-risk, 54Gy/30# low-risk

Healthcare NHS Trust Primary:65Gy/30#; PORT: 60Gy/30# Small field larynx

55Gy/20# (>80 or significant comorbidities) or deferred during peak)

Weston Park Cancer Centre Primary:70Gy/35# PORT: 60-66Gy/30-33#

Mostly no change. If small volume or DAHANCA (68Gy/34# x 6/ week)

Royal Marsden Hospital Primary: 65Gy in 30# PORT: 60Gy/30# No change Clatterbridge Cancer centre Primary:70Gy/35# PORT: 60Gy/30# Primary: Selected patients: 65Gy/30#

Smaller volumes: 55Gy/20#; T1 Larynx: 50Gy/16# option

East Primary:70Gy/35# PORT: 66Gy/33# Primary: 70Gy/35# for young patients

West Primary:70Gy/35# PORT: 60-66Gy/30-33# Primary:55Gy/20# (selected patients)

Oxford University Hospitals Primary: 65Gy/30# PORT: 60Gy/30# No change

Aberdeen Royal Infirmary Primary: 65Gy/30# (Nasopharynx 70Gy/33#, early glottis 55Gy/20#)

Change in feeding tube practice? Yes/No

Change in radiotherapy practice? Yes/No

Radical RT dose fractionation change All patients or selected patients (co-morbidities)? Primary: 65Gy/30 to? PORT: 60Gy/30 fractions to?

Pallitive RT dose fractionation change? Yes/No c) RT delineation Did you change the tumour and/or prophylactic nodal volume delineated? What are the changes?

Change in systemic treatment practice? Yes/No a) Was neoadjuvant chemotherapy given as per your usual practice? b) Was the concurrent chemotherapy omitted or changed? -omission of chemotherapy? -change of cisplatin to carboplatin? -change of 3-weekly to weekly chemotherapy or the other way round?

Any change of surgery practice impacting primary treatment modality (e.g. primary surgery to primary RT

Any change of HN radiology input and practice impacting on patients' care? -Reduced input from radiologists in tumour volume contouring? Yes/No/NA -Decrease in capacity in carrying out scans

Change of pathology practice impact on patients' treatment?

Change of dental service input impact on patients? -any change of baseline screening for patients before radiotherapy? Yes/No/NA -any change in post-treatment monitoring? Yes/No/NA

Any other modifications during this time?

Highlights:  We investigated the effect of COVID-19 pandemic in the treatment practice of head and neck oncology patients in the UK  There is variability in practice in feeding tube policy, radiotherapy fractionation and schedule as well as concurrent chemotherapy and palliative systemic treatment use across the UK oncology centres  15/23 participating centres (65%) changed to either a hypofractionation or acceleration schedule during COVID-19 pandemic  12/23 participating centres (56.5%) followed selective omission of concurrent chemoradiotherapy  There are underlying variations across UK centres for the standard practice as well as treatment modifications; a timely consensus on head and neck cancer management and guidance on treatment modifications for future pandemic is required